PMID- 35833303
OWN - NLM
STAT- MEDLINE
DCOM- 20230103
LR  - 20230829
IS  - 1592-8721 (Electronic)
IS  - 0390-6078 (Print)
IS  - 0390-6078 (Linking)
VI  - 108
IP  - 1
DP  - 2023 Jan 1
TI  - Allogeneic transplant following CAR T-cell therapy for large B-cell lymphoma.
PG  - 98-109
LID - 10.3324/haematol.2022.281242 [doi]
AB  - Allogeneic hematopoietic cell transplantation (alloHCT) can potentially salvage 
      large B-cell lymphoma (LBCL) patients experiencing treatment failure after 
      chimeric antigen receptor T-cell therapy (CAR T). Nonetheless, data on the 
      efficacy and toxicities of alloHCT after receipt of CAR T are limited. We report 
      a multicenter retrospective study assessing the safety, toxicities, and outcomes 
      of alloHCT in LBCL patients following CAR T failure. Eighty-eight patients with 
      relapsed, refractory LBCL received an alloHCT following anti-CD19 CAR T failure. 
      The median number of lines of therapy between CAR T infusion and alloHCT was one 
      (range, 0-7). Low intensity conditioning was used in 77% (n=68) and peripheral 
      blood was the most common graft source (86%, n=76). The most common donor types 
      were matched unrelated donor (39%), followed by haploidentical (30%) and matched 
      related donor (26%). Median follow-up of survivors was 15 months (range, 1-72). 
      One-year overall survival, progression-free survival, and graft-versus-host 
      disease-free relapse-free survival were 59%, 45%, and 39% respectively. One-year 
      non-relapse mortality and progression/relapse were 22% and 33% respectively. On 
      multivariate analysis, <2 lines of intervening therapy between CAR T and alloHCT 
      and complete response at time of alloHCT were associated with better outcomes. In 
      conclusion, alloHCT after CAR T failure can provide durable remissions in a 
      subset of patients.
FAU - Zurko, Joanna
AU  - Zurko J
AD  - University of Wisconsin Carbone Comprehensive Cancer Center, University of 
      Wisconsin, Madison, WI.
FAU - Ramdial, Jeremy
AU  - Ramdial J
AD  - The University of Texas MD Anderson Cancer Center, Department of Stem Cell 
      Transplantation, Division of Cancer Medicine, Houston, TX.
FAU - Shadman, Mazyar
AU  - Shadman M
AD  - Fred Hutchinson Cancer Research Center and University of Washington, Seattle, WA.
FAU - Ahmed, Sairah
AU  - Ahmed S
AD  - The University of Texas MD Anderson Cancer Center, Department of Stem Cell 
      Transplantation, Division of Cancer Medicine, Houston, TX.
FAU - Szabo, Aniko
AU  - Szabo A
AD  - University of Wisconsin Carbone Comprehensive Cancer Center, University of 
      Wisconsin, Madison, WI.
FAU - Iovino, Lorenzo
AU  - Iovino L
AD  - Fred Hutchinson Cancer Research Center and University of Washington, Seattle, WA.
FAU - Tomas, Ana Alarcon
AU  - Tomas AA
AD  - Memorial Sloan Kettering Cancer Center, New York, NY.
FAU - Sauter, Craig
AU  - Sauter C
AD  - Memorial Sloan Kettering Cancer Center, New York, NY.
FAU - Perales, Miguel-Angel
AU  - Perales MA
AD  - Memorial Sloan Kettering Cancer Center, New York, NY.
FAU - Shah, Nirav N
AU  - Shah NN
AD  - University of Wisconsin Carbone Comprehensive Cancer Center, University of 
      Wisconsin, Madison, WI.
FAU - Acharya, Utkarsh H
AU  - Acharya UH
AD  - Dana-Farber Cancer Institute, Department of Medical Oncology, Boston, MA.
FAU - Jacobson, Caron
AU  - Jacobson C
AD  - Dana-Farber Cancer Institute, Department of Medical Oncology, Boston, MA.
FAU - Soiffer, Robert J
AU  - Soiffer RJ
AD  - Dana-Farber Cancer Institute, Department of Medical Oncology, Boston, MA.
FAU - Wang, Trent
AU  - Wang T
AD  - Sylvester Comprehensive Cancer Center, Division of Transplantation and Cellular 
      Therapy, Miami, FL.
FAU - Komanduri, Krishna V
AU  - Komanduri KV
AD  - Sylvester Comprehensive Cancer Center, Division of Transplantation and Cellular 
      Therapy, Miami, FL.
FAU - Jaglowski, Samantha
AU  - Jaglowski S
AD  - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, The 
      Ohio State University, Columbus, OH.
FAU - Kittai, Adam S
AU  - Kittai AS
AD  - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, The 
      Ohio State University, Columbus, OH.
FAU - Denlinger, Nathan
AU  - Denlinger N
AD  - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, The 
      Ohio State University, Columbus, OH.
FAU - Iqbal, Madiha
AU  - Iqbal M
AD  - Mayo Clinic, Division of Hematology-Oncology and Blood and Marrow Transplantation 
      and Cellular Therapy Program, Jacksonville, FL.
FAU - Kharfan-Dabaja, Mohamed A
AU  - Kharfan-Dabaja MA
AD  - Mayo Clinic, Division of Hematology-Oncology and Blood and Marrow Transplantation 
      and Cellular Therapy Program, Jacksonville, FL.
FAU - Ayala, Ernesto
AU  - Ayala E
AD  - Mayo Clinic, Division of Hematology-Oncology and Blood and Marrow Transplantation 
      and Cellular Therapy Program, Jacksonville, FL.
FAU - Chavez, Julio
AU  - Chavez J
AD  - H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL.
FAU - Jain, Michael
AU  - Jain M
AD  - H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL.
FAU - Locke, Frederick L
AU  - Locke FL
AD  - H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL.
FAU - Samara, Yazeed
AU  - Samara Y
AD  - City of Hope, Department of Hematology and Hematopoietic Cell Transplantation, 
      Duarte, CA.
FAU - Budde, Lihua E
AU  - Budde LE
AD  - City of Hope, Department of Hematology and Hematopoietic Cell Transplantation, 
      Duarte, CA.
FAU - Mei, Matthew G
AU  - Mei MG
AD  - City of Hope, Department of Hematology and Hematopoietic Cell Transplantation, 
      Duarte, CA.
FAU - Pia, Alexandra Della
AU  - Pia AD
AD  - John Theurer Cancer Center at Hackensack Meridian Health, NJ, USA; Ernest Mario 
      School of Pharmacy, Rutgers, The State University of New Jersey, Piscataway, NJ.
FAU - Feldman, Tatyana
AU  - Feldman T
AD  - John Theurer Cancer Center at Hackensack Meridian Health, NJ.
FAU - Ahmed, Nausheen
AU  - Ahmed N
AD  - University of Kansas Medical Center, Division of Hematologic Malignancies and 
      Cellular Therapeutics, Westwood, KS.
FAU - Jacobs, Ryan
AU  - Jacobs R
AD  - Levine Cancer Institute/Atrium Health, Charlotte, NC.
FAU - Ghosh, Nilanjan
AU  - Ghosh N
AD  - Levine Cancer Institute/Atrium Health, Charlotte, NC.
FAU - Dholaria, Bhagirathbhai
AU  - Dholaria B
AD  - Vanderbilt-Ingram Cancer Center, Division of Hematology and Oncology, Nashville, 
      TN.
FAU - Oluwole, Olalekan O
AU  - Oluwole OO
AD  - Vanderbilt-Ingram Cancer Center, Division of Hematology and Oncology, Nashville, 
      TN.
FAU - Hess, Brian
AU  - Hess B
AD  - Hollings Cancer Center, Medical University of South Carolina, Charleston, SC.
FAU - Hassan, Ayesha
AU  - Hassan A
AD  - University of Wisconsin Carbone Comprehensive Cancer Center, University of 
      Wisconsin, Madison, WI.
FAU - Kenkre, Vaishalee P
AU  - Kenkre VP
AD  - University of Wisconsin Carbone Comprehensive Cancer Center, University of 
      Wisconsin, Madison, WI.
FAU - Reagan, Patrick
AU  - Reagan P
AD  - Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY.
FAU - Awan, Farrukh
AU  - Awan F
AD  - Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern, 
      Dallas, TX.
FAU - Nieto, Yago
AU  - Nieto Y
AD  - The University of Texas MD Anderson Cancer Center, Department of Stem Cell 
      Transplantation, Division of Cancer Medicine, Houston, TX.
FAU - Hamadani, Mehdi
AU  - Hamadani M
AD  - Medical College of Wisconsin, BMT and Cellular Therapy Program, Division of 
      Hematology and Oncology, Milwaukee, WI.
FAU - Herrera, Alex F
AU  - Herrera AF
AD  - City of Hope, Department of Hematology and Hematopoietic Cell Transplantation, 
      Duarte, CA. aherrera@coh.org.
LA  - eng
GR  - P30 CA008748/CA/NCI NIH HHS/United States
GR  - P50 CA107399/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Multicenter Study
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20230101
PL  - Italy
TA  - Haematologica
JT  - Haematologica
JID - 0417435
RN  - 0 (Receptors, Chimeric Antigen)
RN  - 0 (Antigens, CD19)
SB  - IM
MH  - Humans
MH  - Immunotherapy, Adoptive/adverse effects
MH  - *Receptors, Chimeric Antigen
MH  - Retrospective Studies
MH  - Neoplasm Recurrence, Local/etiology
MH  - *Hematopoietic Stem Cell Transplantation/adverse effects
MH  - *Lymphoma, Large B-Cell, Diffuse/therapy/etiology
MH  - Transplantation, Homologous
MH  - Antigens, CD19
PMC - PMC9827150
EDAT- 2022/07/15 06:00
MHDA- 2023/01/04 06:00
PMCR- 2022/07/14
CRDT- 2022/07/14 03:55
PHST- 2021/04/13 00:00 [received]
PHST- 2022/07/15 06:00 [pubmed]
PHST- 2023/01/04 06:00 [medline]
PHST- 2022/07/14 03:55 [entrez]
PHST- 2022/07/14 00:00 [pmc-release]
AID - 10.3324/haematol.2022.281242 [doi]
PST - epublish
SO  - Haematologica. 2023 Jan 1;108(1):98-109. doi: 10.3324/haematol.2022.281242.